Farther Finance Advisors LLC Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Farther Finance Advisors LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN) by 13.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,083 shares of the company’s stock after buying an additional 706 shares during the period. Farther Finance Advisors LLC’s holdings in AstraZeneca were worth $442,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of AZN. Confluence Investment Management LLC purchased a new stake in AstraZeneca during the 1st quarter worth approximately $27,000. Banque Transatlantique SA purchased a new stake in AstraZeneca during the 4th quarter worth approximately $26,000. Mascagni Wealth Management Inc. purchased a new stake in AstraZeneca during the 4th quarter worth approximately $29,000. CoreCap Advisors LLC grew its position in AstraZeneca by 31.8% during the 4th quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock worth $42,000 after purchasing an additional 155 shares during the last quarter. Finally, Financial Management Professionals Inc. grew its position in AstraZeneca by 34.4% during the 1st quarter. Financial Management Professionals Inc. now owns 781 shares of the company’s stock worth $57,000 after purchasing an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $74.42 on Monday. The company has a current ratio of 0.93, a quick ratio of 0.74 and a debt-to-equity ratio of 0.65. The company has a 50 day simple moving average of $69.81 and a two-hundred day simple moving average of $70.31. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $87.68. The stock has a market cap of $230.80 billion, a price-to-earnings ratio of 32.93, a PEG ratio of 1.42 and a beta of 0.38.

AstraZeneca (NASDAQ:AZN) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The firm had revenue of $13.59 billion during the quarter, compared to analysts’ expectations of $13.71 billion. During the same period in the previous year, the business posted $2.06 EPS. The business’s revenue was up 7.2% compared to the same quarter last year. As a group, analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas began coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an “outperform” rating and a $75.00 target price on the stock. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.